ArticleGlomerular diseases
Nudging Nephrologists in Cardiovascular Risk Assessment and Management in Glomerular Diseases Treated with Immunosuppressants: An Implementation Study.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glomerulonephritis and its treatment may be associated with cardiometabolic disease, so optimizing glycaemic and lipid control is important to mitigate cardiovascular risk. We aimed to evaluate the impact of an electronic medical record (EMR)-based physician prompt on glycaemic and lipid management among older adults with glomerulonephritis receiving immunosuppressive therapy. Methods: This was a single-centre implementation study with a pre-post-design. We included adults ≥40 years old with active glomerulonephritis treated with immunosuppressants who received the physician prompt between July 2022 and June 2024. Data at 6-monthly intervals were obtained from the EMR. We compared the prevalence of glycaemic and lipid evaluation during follow-up visits before and after the intervention using mixed-effects logistic regression models. Results: A total of 192 patients (median age 58 [interquartile range: 48, 69] years) with 859 visits were included: 474 visits prior to the intervention and 385 visits after its implementation. The most frequent causes of glomerulonephritis were lupus nephritis (26.9%), IgA nephropathy (20.4%), and ANCA-associated vasculitis (15.7%). Glycaemic evaluation was performed at 51.7% and 69.6% of follow-up visits before and after intervention, respectively. Glycaemic evaluation was significantly more likely at post- compared with pre-intervention visits (OR = 2.42 [95% CI: 1.73, 3.36]) after accounting for patients and physicians as random effects, and after adjusting for age, sex, kidney function, follow-up clinic type and duration, and RAS blocker and statin therapy: OR = 2.38 (95% CI: 1.69, 3.38). Fasting lipid was performed at 43.7% and 42.9% of follow-up visits before and after intervention, respectively, and was not different pre- and post-intervention. Conclusion: A physician-directed nudge significantly increased glycaemic evaluation but not lipid evaluation in older patients with glomerulonephritis treated with immunosuppressants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.